Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21917714
Andreu-PĂ©rez P, et al. (2011) Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF. Sci Signal 4, ra58 21917714
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
EGF increase
phorbol_ester increase
MSH no change compared to control
FGF1 increase
FGF2 increase
5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases
EGF PRMT5 (human) augment treatment-induced increase mutant
5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases
RAF1 (human) increase R563K mutant
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  signaling pathway regulation
Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
EGF increase
phorbol_ester increase
MSH no change compared to control
FGF1 increase
FGF2 increase
5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases
EGF PRMT5 (human) augment treatment-induced increase mutant
5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases
RAF1 (human) increase R563K mutant
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  signaling pathway regulation
Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
EGF increase
phorbol_ester increase
MSH no change compared to control
FGF1 increase
FGF2 increase
5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases
EGF PRMT5 (human) augment treatment-induced increase mutant
5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases
RAF1 (human) increase R563K mutant
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  signaling pathway regulation
Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
EGF increase
phorbol_ester increase
MSH no change compared to control
FGF1 increase
FGF2 increase
5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases
EGF PRMT5 (human) augment treatment-induced increase mutant
5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases
RAF1 (human) increase R563K mutant
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  signaling pathway regulation
Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

T203-p - ERK1 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
EGF increase
phorbol_ester increase
MSH no change compared to control
FGF1 increase
FGF2 increase
5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases
EGF PRMT5 (human) augment treatment-induced increase mutant
5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases
RAF1 (human) increase R563K mutant
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  signaling pathway regulation
Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

Y205-p - ERK1 (mouse)
Modsite: HtGFLtEyVAtRWyR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
EGF increase
phorbol_ester increase
MSH no change compared to control
FGF1 increase
FGF2 increase
5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases
EGF PRMT5 (human) augment treatment-induced increase mutant
5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases
RAF1 (human) increase R563K mutant
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  signaling pathway regulation
Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

T183-p - ERK2 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
EGF increase
phorbol_ester increase
MSH no change compared to control
FGF1 increase
FGF2 increase
5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases
EGF PRMT5 (human) augment treatment-induced increase mutant
5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases
RAF1 (human) increase R563K mutant
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  signaling pathway regulation
Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

Y185-p - ERK2 (mouse)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
EGF increase
phorbol_ester increase
MSH no change compared to control
FGF1 increase
FGF2 increase
5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases
EGF PRMT5 (human) augment treatment-induced increase mutant
5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases
RAF1 (human) increase R563K mutant
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  signaling pathway regulation
Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

S218-p - MEK1 (mouse)
Modsite: VSGQLIDsMANsFVG SwissProt Entrez-Gene
Orthologous residues
MEK1 (human): S218‑p, MEK1 iso2 (human): S192‑p, MEK1 (mouse): S218‑p, MEK1 (rat): S218‑p, MEK1 (rabbit): S218‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
5'-methylthioadenosine HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
DDATHF HGF augment treatment-induced increase
DDATHF no change compared to control

S222-p - MEK1 (mouse)
Modsite: LIDsMANsFVGTRSY SwissProt Entrez-Gene
Orthologous residues
MEK1 (human): S222‑p, MEK1 iso2 (human): S196‑p, MEK1 (mouse): S222‑p, MEK1 (rat): S222‑p, MEK1 (rabbit): S222‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
5'-methylthioadenosine HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
DDATHF HGF augment treatment-induced increase
DDATHF no change compared to control

S222-p - MEK2 (mouse)
Modsite: VsGQLIDsMANsFVG SwissProt Entrez-Gene
Orthologous residues
MEK2 (human): S222‑p, MEK2 (mouse): S222‑p, MEK2 (rat): S222‑p, MEK2 (chicken): S220‑p, MEK2 (cow): S222‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
5'-methylthioadenosine HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
DDATHF HGF augment treatment-induced increase
DDATHF no change compared to control

S226-p - MEK2 (mouse)
Modsite: LIDsMANsFVGTRSY SwissProt Entrez-Gene
Orthologous residues
MEK2 (human): S226‑p, MEK2 (mouse): S226‑p, MEK2 (rat): S226‑p, MEK2 (chicken): S224‑p, MEK2 (cow): S226‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
5'-methylthioadenosine HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
DDATHF HGF augment treatment-induced increase
DDATHF no change compared to control

Y1232-p - Met (mouse)
Modsite: rDMyDKEyysVHNKt SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1234‑p, Met iso2 (human): Y1252‑p, Met (mouse): Y1232‑p, Met (rat): Y1235‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
5'-methylthioadenosine HGF no effect upon treatment-induced increase

Y1233-p - Met (mouse)
Modsite: DMyDKEyysVHNKtG SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1235‑p, Met iso2 (human): Y1253‑p, Met (mouse): Y1233‑p, Met (rat): Y1236‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
5'-methylthioadenosine HGF no effect upon treatment-induced increase

T203-p - ERK1 (rat)
Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  hepatocyte-liver, PC-12 (chromaffin)
Cellular systems studied:  cell lines, primary cultured cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
EGF increase
phorbol_ester increase
MSH no change compared to control
FGF1 increase
FGF2 increase
5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases
EGF PRMT5 (human) augment treatment-induced increase mutant
5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases
RAF1 (human) increase R563K mutant
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  signaling pathway regulation
Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

Y205-p - ERK1 (rat)
Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  hepatocyte-liver, PC-12 (chromaffin)
Cellular systems studied:  cell lines, primary cultured cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
EGF increase
phorbol_ester increase
MSH no change compared to control
FGF1 increase
FGF2 increase
5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases
EGF PRMT5 (human) augment treatment-induced increase mutant
5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases
RAF1 (human) increase R563K mutant
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  signaling pathway regulation
Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

T183-p - ERK2 (rat)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  hepatocyte-liver, PC-12 (chromaffin)
Cellular systems studied:  cell lines, primary cultured cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
EGF increase
phorbol_ester increase
MSH no change compared to control
FGF1 increase
FGF2 increase
5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases
EGF PRMT5 (human) augment treatment-induced increase mutant
5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases
RAF1 (human) increase R563K mutant
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  signaling pathway regulation
Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

Y185-p - ERK2 (rat)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo western blotting
Disease tissue studied:  adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  hepatocyte-liver, PC-12 (chromaffin)
Cellular systems studied:  cell lines, primary cultured cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
EGF increase
phorbol_ester increase
MSH no change compared to control
FGF1 increase
FGF2 increase
5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase
U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase
leucine HGF augment treatment-induced increase
HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases
EGF PRMT5 (human) augment treatment-induced increase mutant
5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases
RAF1 (human) increase R563K mutant
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  signaling pathway regulation
Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation